What has been exposed by Japanese pharmaceutical companies that have been focused on counterfeiting for thirty years?

On the 26th local time, Yomiuri Shimbun in Japan reported that in the summer of 2022, relevant departments discovered during inspections that the Japanese pharmaceutical company "Jidong" was exposed to have defects in its gastrointestinal drug "Zhenglu Wan", and requested the company to proactively recall 5.16 million products. The report also stated that the pharmaceutical company has been falsifying test results for at least 30 years.

It is reported that the Japanese pharmaceutical company "Jidong" has been ordered by the Toyama Prefecture government to stop production and sales of the gastrointestinal medicine "Zhenglu Pill" due to the production of insufficient ingredients and the shipment of fake data. The production period is 23 days and 22 days, respectively. The decision will be officially implemented from April 30th.

However, Jidong Company has been falsifying drug trial data for more than 30 years, as data shows. Faced with doubts from the public and relevant parties, Jidong Company acknowledges that it has been tampering with drug test results since 30 years ago and apologizes for its lack of awareness of compliance with regulations. The company promises to take this incident seriously, strive to restore consumer trust, and thoroughly investigate to prevent similar incidents from happening again.

The best-selling Japanese Zhenglu Pill in China is Daiko Pharmaceuticals' Trumpet brand Zhenglu Pill, followed by Jidong brand Zhenglu Pill, and this time it was found that Jidong Zhenglu Pill was fake. According to media reports, the main problem with Jidong Zhenglu Pill is insufficient active ingredients, and the data in the test reports is fake. For 30 years, fake test reports have been used to impersonate qualified drugs.

Japan has always had a good reputation in the pharmaceutical industry, especially in some well-known fields where people have become divine medicines. Various people boast about the wonders of Japanese medicine, and Japanese medicine has always had a good market share in Asia. However, reality shows that all of this is actually false and just lies.

The reason why Japanese drugs can have a reputation, and they have done a great relationship, after the experiment, they rely on data to sell to the world, but people did not expect that the so-called data in Japan is false.

However, it is unexpected that the so-called data in Japan is all fake.

For drugs, if their active ingredients are insufficient, their therapeutic effect will definitely be insufficient. This kind of medicine usually won't cause any major problems when taken, but it won't cure the disease for a long time. But such a pharmaceutical factory has been selling fake drugs for 30 years, ignoring the health of consumers and patients. This problem is really too bad. This also fully reflects that Japan's regulatory authorities have not done enough in monitoring drug sampling.

The Japanese Masaru, who has always been trusted in the minds of consumers, was exposed for 30 years of focused counterfeiting. The news was shocking. But in fact, similar pharmaceutical company scandals in Japan are no longer new.

Since March this year, the scandal involving the detection of highly toxic substance "soft hair penicillic acid" in health products containing red yeast by Kobayashi Pharmaceutical in Japan has attracted widespread attention. Japanese food and alcohol manufacturers have announced the recycling of red yeast related products produced by Kobayashi Pharmaceuticals. At present, multiple consumers have died or been hospitalized due to taking health products containing red yeast from Xiaolin Pharmaceutical.

Previously, data from the Japanese Ministry of Health, Labour and Welfare showed that as of the 18th of this month, 5 consumers who had taken Kobayashi Pharmaceuticals health products containing red yeast had died, and the number of hospitalizations and visits to hospitals had increased to 240，the number of people seeking medical treatment at the hospital has increased to 1434. These data have brought great concerns to Japanese society.

The controversy surrounding Kobayashi Pharmaceutical's red yeast is still under investigation, and the current "Zhenglu Pill" has flaws. Amidst numerous mysteries, the blow to Japanese pharmaceutical companies is enormous, and public opinion is still fermenting. The international community strongly condemns the fraudulent behavior of Japanese pharmaceutical companies and their negative response strategies to deal with the public's attitude. If Japan cannot properly handle the crisis faced by pharmaceutical companies, it will seriously affect the image and trust of Japanese drugs in the public, causing a fatal blow to pharmaceutical companies.